Medical Reimbursement Supporting the Nebulizer Market Growth 2019: GE Healthcare Ltd, Agilent Technologies, GF Health Products, Philips Healthcare CareFusion Corporation, PARI Respiratory Equipment, Covidien plc

There are guidelines laid for nebulizers which facilitates its proper usage. The Centers for Medicare & Medicaid Services, and United HealthCare Services, Inc. have defined guidelines for the proper usage of nebulizers in different respiratory issues. In addition to that there are various reimbursement policies that fuel the growth of the market, for instance, policies by Medicaid & Healthcare Partnership in 2012 helped in the easy purchase of nebulizers. Under Hawaii Medical Service Association, in 2014, several cover plans were made for the easy purchases of small volume and large volume nebulizers.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/545

Since nebulization is a spraying technique, therefore the dispersion and wastage of the drug during delivery to the respiratory tract is one of the major restraint for the growth of nebulizers market. Moreover, low consumer switching cost and availability of alternative therapies increases the threat of substitute products. By geography, North America holds the major share in the global nebulizers market because of the availability of reimbursement and increasing incidence of respiratory diseases.

The advanced nebulizers that features aerosol drug delivery technology with minimal drug wastage is expected to drive the nebulizers market growth. Patients play a vigorous role in supervising their diseases by choosing for devices that assist them in diagnosis and treatment at the comfort of their own homes. This shift in patient preferences will strengthen the global nebulizer market growth scenario in the near future. Also the rise in respiratory cases form a major factor. According to World Health Organization (WHO), around 15.7 million people were reported with Chronic Obstructive Pulmonary Disease (COPD) in the U.S. in 2016 which showed a significant increase of 6.4% from 2015.

Nebulizers are also for a variety of diagnostic procedures among which the principal one is in diagnosis of lung function and bronchial activities. This has also added to the rise in demand for nebulizers in the market by the professionals for clinical use and monitoring of various associated respiratory disorders.

The players are undertaking various clinical trials and development activities in an endeavor to improve therapeutic effect of the drug. Theravance Biopharma and Mylan announced the initiation of phase 3 studies of revefenacin at the American Thoracic Society (ATS) International Conference in 2017. Revefenacin is a once-daily long acting muscarinic antagonist (LAMA) nebulized therapy. Development of such drugs intended to be delivered via nebulization will also support propelling the growth for nebulizers market. Also Vectura received FDA approval to start testing a smart technology of nebulizers to improve asthma therapies in children.

Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/545

Key players in the global nebulizers market are GE Healthcare Ltd, Agilent Technologies, GF Health Products, Philips Healthcare CareFusion Corporation, PARI Respiratory Equipment, Covidien plc and Omron Healthcare Co.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.